---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-409335"
form_type: "8-K"
ticker: "SGMT"
cik: "0001400118"
company_name: "Sagimet Biosciences Inc."
filed_at: "2026-09-30T22:00:51+00:00"
generated_at: "2026-10-12T14:11:52.776137+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sagimet Biosciences prices $115M offering: 8.75M shares at $10, 2.75M pre-funded warrants for Phase 3 acne trial

## Summary
- Offering: 8,750,010 shares at $10.00 and pre-funded warrants for 2,750,010 shares at $9.9999 (gross ~$115M); net proceeds ~$107.5M; close Oct 1, 2026.
- Proceeds fund Phase 3 trial of denifanstat in acne, pre-launch activities, TVB-3567 through Phase 2 topline, topical FASN inhibitor program to IND, and general corporate purposes.
- Pre-funded warrants exercisable immediately at $0.0001/share; 4.99% beneficial ownership cap (9.99% at purchaser election), adjustable to 19.99% with 61 days' notice.
- Leerink, TD Securities, Guggenheim and Oppenheimer are joint book-running managers; Canaccord Genuity, H.C. Wainwright, JonesTrading and Clear Street are co-lead managers.

## SEC filing metadata
- accession: 0001193125-26-409335
- form_type: 8-K
- ticker: SGMT
- cik: 0001400118
- company_name: Sagimet Biosciences Inc.
- filed_at: 2026-09-30T22:00:51+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1400118/000119312526409335/0001193125-26-409335-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1400118/000119312526409335/d136610d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-409335
- JSON: https://secwatch.observer/filing/0001193125-26-409335.json
- Plain text: https://secwatch.observer/filing/0001193125-26-409335.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.